Enhanced phosphorylation of p53 by ATM in response to DNA damage

Science

Volumn 281, Issue 5383, 1998, Pages 1674-1677

  Banin, S ^a   Moyal, L ^a   Shieh, S Y ^a   Taya, Y ^a   Anderson, C W ^a   Chessa, L ^a   Smorodinsky, N I ^a   Prives, C ^a   Reiss, Y ^a   Shiloh, Y ^a   Ziv, Y ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN KINASE; PROTEIN P53;

APOPTOSIS; ARTICLE; ATAXIA TELANGIECTASIA; DNA DAMAGE; DNA STRAND BREAKAGE; ENZYME ACTIVITY; GENE MUTATION; IMMUNOBLOTTING; MISSENSE MUTATION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANDROSTADIENES; ATAXIA TELANGIECTASIA; CARRIER PROTEINS; CELL CYCLE PROTEINS; CELL LINE; DNA DAMAGE; DNA-BINDING PROTEINS; ENZYME INHIBITORS; HUMANS; MUTATION; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; PROTEINS; RECOMBINANT PROTEINS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS; ZINOSTATIN;

EID: 0032508504     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.281.5383.1674     Document Type: Article

References (39)

1. A. J. Levine, Cell 88, 323 (1997).
2. M. Lavin and Y. Shiloh, Annu. Rev. Immunol. 15, 177 (1997); Y. Shiloh, Annu. Rev. Genet. 31, 635 (1997); R. A. Gatti, in The Genetic Basis of Human Cancer, B. Vogelstein and K. W. Kinzler, Eds. (McCraw-Hill, New York, 1998), pp. 275-300; C. Barlow et al., Cell 86, 159 (1996); Y. Xu and D. Baltimore, Genes Dev. 10, 2401 (1996); S. E. Morgan and M. B. Kastan, Adv. Cancer Res. 71, 1 (1997).
3. M. Lavin and Y. Shiloh, Annu. Rev. Immunol. 15, 177 (1997); Y. Shiloh, Annu. Rev. Genet. 31, 635 (1997); R. A. Gatti, in The Genetic Basis of Human Cancer, B. Vogelstein and K. W. Kinzler, Eds. (McCraw-Hill, New York, 1998), pp. 275-300; C. Barlow et al., Cell 86, 159 (1996); Y. Xu and D. Baltimore, Genes Dev. 10, 2401 (1996); S. E. Morgan and M. B. Kastan, Adv. Cancer Res. 71, 1 (1997).
4. M. Lavin and Y. Shiloh, Annu. Rev. Immunol. 15, 177 (1997); Y. Shiloh, Annu. Rev. Genet. 31, 635 (1997); R. A. Gatti, in The Genetic Basis of Human Cancer, B. Vogelstein and K. W. Kinzler, Eds. (McCraw-Hill, New York, 1998), pp. 275-300; C. Barlow et al., Cell 86, 159 (1996); Y. Xu and D. Baltimore, Genes Dev. 10, 2401 (1996); S. E. Morgan and M. B. Kastan, Adv. Cancer Res. 71, 1 (1997).
5. M. Lavin and Y. Shiloh, Annu. Rev. Immunol. 15, 177 (1997); Y. Shiloh, Annu. Rev. Genet. 31, 635 (1997); R. A. Gatti, in The Genetic Basis of Human Cancer, B. Vogelstein and K. W. Kinzler, Eds. (McCraw-Hill, New York, 1998), pp. 275-300; C. Barlow et al., Cell 86, 159 (1996); Y. Xu and D. Baltimore, Genes Dev. 10, 2401 (1996); S. E. Morgan and M. B. Kastan, Adv. Cancer Res. 71, 1 (1997).
6. M. Lavin and Y. Shiloh, Annu. Rev. Immunol. 15, 177 (1997); Y. Shiloh, Annu. Rev. Genet. 31, 635 (1997); R. A. Gatti, in The Genetic Basis of Human Cancer, B. Vogelstein and K. W. Kinzler, Eds. (McCraw-Hill, New York, 1998), pp. 275-300; C. Barlow et al., Cell 86, 159 (1996); Y. Xu and D. Baltimore, Genes Dev. 10, 2401 (1996); S. E. Morgan and M. B. Kastan, Adv. Cancer Res. 71, 1 (1997).
7. M. Lavin and Y. Shiloh, Annu. Rev. Immunol. 15, 177 (1997); Y. Shiloh, Annu. Rev. Genet. 31, 635 (1997); R. A. Gatti, in The Genetic Basis of Human Cancer, B. Vogelstein and K. W. Kinzler, Eds. (McCraw-Hill, New York, 1998), pp. 275-300; C. Barlow et al., Cell 86, 159 (1996); Y. Xu and D. Baltimore, Genes Dev. 10, 2401 (1996); S. E. Morgan and M. B. Kastan, Adv. Cancer Res. 71, 1 (1997).
8. K. Savitsky et al., Science 268, 1749 (1995); K. Savitsky et al., Hum. Mol. Genet. 4, 2025 (1995).
9. K. Savitsky et al., Science 268, 1749 (1995); K. Savitsky et al., Hum. Mol. Genet. 4, 2025 (1995).
10. M. F. Hoekstra, Curr. Opin. Genet. Dev. 7, 170 (1997).
11. K. O. Hartley et al., CeH 82, 849 (1995); E. J. Brown et al., Nature 377, 441 (1995); G. J. Brunn et al., EMBO J. 15, 5256 (1996); G. J. Brunn et al., Science 277, 99 (1997).
12. K. O. Hartley et al., CeH 82, 849 (1995); E. J. Brown et al., Nature 377, 441 (1995); G. J. Brunn et al., EMBO J. 15, 5256 (1996); G. J. Brunn et al., Science 277, 99 (1997).
13. K. O. Hartley et al., CeH 82, 849 (1995); E. J. Brown et al., Nature 377, 441 (1995); G. J. Brunn et al., EMBO J. 15, 5256 (1996); G. J. Brunn et al., Science 277, 99 (1997).
14. K. O. Hartley et al., CeH 82, 849 (1995); E. J. Brown et al., Nature 377, 441 (1995); G. J. Brunn et al., EMBO J. 15, 5256 (1996); G. J. Brunn et al., Science 277, 99 (1997).
15. L. Moyal et al., in preparation.
16. 32P]adenosine triphosphate (ATP), and ATP to a final concentration of 5 μM were added, and the reaction mixtures were incubated at 30°C for 3 to 15 min. After electrophoresis in SDS-polyacrylamide gels, the reaction products were visualized by autoradiography.
17. T.-A. Lin et al., Science 266, 653 (1994).
18. S. Banin et al., unpublished data.
19. Y. Ziv et al., Oncogene 15, 159 (1997).
20. S. Gilad et al., Hum. Mol. Genet. 5, 433 (1996).
21. S. Gilad et al., Am. J. Hum. Genet. 62, 551 (1998).
22. M. T. Ui, T. Okada, K. Hazeki, O. Hazeki, Trends Biochem. Sci. 20, 303 (1995); M. P. Wymann et al., Mol. Cell. Biol. 16, 1722 (1996).
23. M. T. Ui, T. Okada, K. Hazeki, O. Hazeki, Trends Biochem. Sci. 20, 303 (1995); M. P. Wymann et al., Mol. Cell. Biol. 16, 1722 (1996).
24. J. D. Siliciano et al., Genes Dev. 11, 3471 (1997).
25. S.-Y. Shieh, M. Ikeda, Y. Taya, C. Prives, Cell 91, 325 (1997).
26. D. Watters et al., Oncogene 14, 1911 (1997).
27. M. Kitagawa et al., EMBO J. 15, 7060 (1996); L. J. Ko et al., Mol. Cell. Biol. 17, 7220 (1997).
28. M. Kitagawa et al., EMBO J. 15, 7060 (1996); L. J. Ko et al., Mol. Cell. Biol. 17, 7220 (1997).
29. N. D. Lakin et al., Oncogene 13, 2707 (1996); K. D. Brown et al., Proc. Natl. Acad. Sci. U.S.A. 94, 1840 (1997).
30. N. D. Lakin et al., Oncogene 13, 2707 (1996); K. D. Brown et al., Proc. Natl. Acad. Sci. U.S.A. 94, 1840 (1997).
31. I. H. Goldberg and L. S. Kappen, in Enediyne Antibiotics as Antitumor Agents, D. B. Borders and T. W. Doyle, Eds. (Dekker, New York, 1995), pp. 327-362.
32. K. S. Keegan et al., Genes Dev. 10, 2423 (1996); M. Jung et al., Cancer Res. 57, 24 (1997).
33. K. S. Keegan et al., Genes Dev. 10, 2423 (1996); M. Jung et al., Cancer Res. 57, 24 (1997).
34. M. Fiscella et al., Oncogene 8, 1519 (1993).
35. J. Momand, G. P. Zambetti, D. C. Olson, D. George, A. J. Levine, Cell 69, 1237 (1992); J. D. Oliner et al., Nature 362, 857 (1993).
36. J. Momand, G. P. Zambetti, D. C. Olson, D. George, A. J. Levine, Cell 69, 1237 (1992); J. D. Oliner et al., Nature 362, 857 (1993).
37. Y. Haupt, R. Maya, A. Kazaz, M. Oren, Nature 387, 286 (1997); M. H. G. Kubbutat, S. N. Jones, K. H. Vousden, ibid., p. 299.
38. Y. Haupt, R. Maya, A. Kazaz, M. Oren, Nature 387, 286 (1997); M. H. G. Kubbutat, S. N. Jones, K. H. Vousden, ibid., p. 299.
39. We thank M. Hoekstra for the cell line G361; J. Ahn for p53-derived constructs; E. Lee, R. Nechushtai, G. Rathbun, and B. Price for useful advice; and F. Zetland for manuscript editing. Supported by the A-T Medical Research Foundation, the A-T Children's Project, NIH grant NS31763, the Thomas Appeal (A-T Medical Research Trust), the A-T Appeal, and a fellowship of the Council for Higher Education of the State of Israel (S.B.).